Ferrostatin-1 (Fer-1): Selective Ferroptosis Inhibitor for Regulated Cell Death Studies

Executive Summary: Ferrostatin-1 (Fer-1, SKU A4371) is a potent and selective inhibitor of ferroptosis, acting through the reduction of lipid reactive oxygen species (ROS) and inhibition of membrane lipid peroxidation [APExBIO Product Page]. It demonstrates an EC50 of ~60 nM against erastin-induced ferroptosis in cellular assays (Li et al., 2025). Fer-1 is effective in increasing the viability of tracheal basal cells and neurons under oxidative stress. It is soluble in DMSO and ethanol, but not in water, and is used broadly for mechanistic and disease model studies in cancer, neurodegeneration, and ischemic injury [internal: Mechanistic Review]. All claims are grounded in peer-reviewed literature and product documentation.

Biological Rationale

Ferroptosis is a regulated form of iron-dependent, non-apoptotic cell death characterized by the accumulation of lipid peroxides (Li et al., 2025). This process is distinct from apoptosis and necrosis, being caspase-independent and reliant on iron-mediated oxidative damage to membrane lipids. Ferroptosis impacts diverse biological contexts, including cancer progression, neurodegeneration, ischemic injury, and tissue regeneration. Inhibition of ferroptosis is critical for preserving cellular viability in models where oxidative lipid damage is a primary driver of pathology. Ferrostatin-1 (Fer-1) provides researchers with a highly selective chemical probe to dissect these pathways, enabling mechanistic studies and therapeutic explorations across multiple disease models [internal: Standardization]. This article extends previous resources by integrating quantitative benchmarks and highlighting direct applications in tissue engineering.

Mechanism of Action of Ferrostatin-1 (Fer-1)

Ferrostatin-1 acts as a radical-trapping antioxidant, selectively inhibiting ferroptosis via suppression of lipid reactive oxygen species (ROS) and consequent reduction of phospholipid peroxidation. Experimental evidence demonstrates that Fer-1 prevents the propagation of lipid peroxyl radicals, particularly in the presence of iron and in the context of erastin or RSL3-induced ferroptosis. It does not inhibit other forms of regulated cell death such as apoptosis or necroptosis (Li et al., 2025). In tracheal basal cells, Fer-1 treatment (1 μM, 48 h, in vitro) significantly reduces ROS and Fe²⁺ accumulation, preserves mitochondrial structure, and enhances ATP production. The action is direct and dose-dependent, with an EC50 of ~60 nM in standard cell-based ferroptosis assays [APExBIO].

Evidence & Benchmarks

• Ferrostatin-1 (Fer-1) inhibits erastin-induced ferroptosis in cellular models with an EC50 of ~60 nM (cell viability assays, 24–48 h) (Li et al., 2025).
• Fer-1 at 1 μM for 48 h significantly reduces ROS and Fe²⁺ in tracheal basal cells, restores ATP levels, and prevents mitochondrial damage (Li et al., 2025).
• In vivo, Fer-1-treated cell-seeded scaffolds accelerate epithelialization and reduce granulation tissue formation in rabbit tissue-engineered trachea models (6-month endpoint) (Li et al., 2025).
• Fer-1 demonstrates high solubility in DMSO (≥149 mg/mL) and ethanol (≥99.6 mg/mL with ultrasound), but is insoluble in water (APExBIO).
• Ferrostatin-1 increases viability of medium spiny neurons and oligodendrocytes under oxidative stress in vitro (internal resource).

Applications, Limits & Misconceptions

Fer-1 is widely used in research targeting iron-dependent oxidative cell death in cancer biology, neurodegeneration, ischemic injury, and tissue engineering. Its specificity enables mechanistic dissection of the lipid peroxidation pathway and supports the development of therapeutic strategies for ferroptosis-associated diseases [internal: Practical Guidance]. This article updates prior internal resources by presenting quantitative in vivo and in vitro benchmarks from recent literature.

Common Pitfalls or Misconceptions

• Fer-1 is not effective against apoptosis or necroptosis; its action is selective for ferroptosis (Li et al., 2025).
• Fer-1 is insoluble in water and must be dissolved in DMSO or ethanol for experimental use (APExBIO).
• Solutions of Fer-1 are not recommended for long-term storage; use freshly prepared aliquots (APExBIO).
• Ferrostatin-1 does not address non-iron-dependent or caspase-dependent cell death mechanisms.
• Therapeutic efficacy in humans is unproven; current use is limited to research applications (Li et al., 2025).

Workflow Integration & Parameters

Ferrostatin-1 (Fer-1) is supplied by APExBIO as a high-purity powder (SKU A4371) for research use. Dissolve Fer-1 in DMSO (≥149 mg/mL) or ethanol (≥99.6 mg/mL, ultrasound-assisted) for stock solutions. For cell-based assays, typical working concentrations range from 0.1–2 μM. Store powder at -20°C, protected from light; avoid repeated freeze-thaw cycles. Solutions should be prepared fresh prior to use. In ferroptosis assays, Fer-1 is applied prior to or concurrent with ferroptosis-inducing agents (e.g., erastin, RSL3). Cell viability, ROS, Fe²⁺, and mitochondrial integrity are commonly measured endpoints. For detailed scenario-driven protocols, see this guide, which this article extends by including direct in vivo evidence for tissue-engineered trachea models.

Conclusion & Outlook

Ferrostatin-1 (Fer-1) is the benchmark selective ferroptosis inhibitor for research applications targeting regulated, iron-dependent oxidative cell death. Its efficacy and selectivity are supported by both in vitro and in vivo studies, including recent advances in tissue engineering (Li et al., 2025). Future work will focus on further elucidating molecular mechanisms and expanding translational applications. For ordering or technical details, see the APExBIO product page.